You are here: Industry Insights > Farxiga

News List

AstraZeneca, Saint Luke’s Mid America Heart Institute Start Farxiga Trial for COVID-19 americanpharmaceuticalreview
April 24, 2020
AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomized, global Phase III trial.
AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF pharmaceutical-business-review
January 09, 2020
AstraZeneca’s Farxiga (dapagliflozin) has been granted priority review from the US Food and Drug Administration (FDA) for a certain population of patients with heart failure.
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction worldpharmanews
January 07, 2020
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failu
AstraZeneca secures FDA priority review for Farxiga pharmaceutical-technology
January 07, 2020
AstraZeneca has secured the US Food and Drug Administration (FDA) priority review for Farxiga (dapagliflozin) to treat heart failure with reduced ejection fraction (HFrEF).
FDA grants Fast Track designation for Farxiga in heart failure worldpharmanews
September 18, 2019
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death...
Fast Track designation given to heart failure treatment europeanpharmaceuticalreview
September 18, 2019
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
FDA fast tracks AstraZeneca's FARXIGA biospectrumasia
August 29, 2019
FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease
FDA grants Fast Track designation for Farxiga in chronic kidney disease worldpharmanews
August 29, 2019
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure...
FDA fast tracks AstraZeneca's FARXIGA biospectrumasia
August 28, 2019
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patient
AstraZeneca's Farxiga pads its case for new heart-helping approval fiercepharma
August 22, 2019
AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But here's something that could ease the pain: New outcomes data showing Farxiga cut cardiovascular risks in heart failure patients—with or wit

Previous page 1 2 3 Next page